Abstract:ImportanceAs cervical cancer screening transitions from Papanicolaou cytologic screening to primary human papillomavirus (HPV) testing worldwide, effective triage tests are needed to decide who among the HPV-positive women should receive further diagnostic evaluation to avoid unnecessary colposcopies and biopsies.ObjectiveTo evaluate the performance of the p16/Ki-67 dual stain (DS) and HPV16/18 genotyping for the triage of HPV-positive women.Design, Setting, and ParticipantsA prospective observational study was conducted within the cervical cancer screening program at Kaiser Permanente Northern California of 3225 HPV-positive women undergoing HPV and Papanicolaou cytologic testing with a valid DS result from September 16 to October 31, 2015, with follow-up through December 31, 2018.ExposuresHuman papillomavirus screening with partial genotyping and cytologic triage compared with DS triage.Main Outcomes and MeasuresCervical intraepithelial neoplasia grade 3 or more severe (CIN3+) and grade 2 or more severe (CIN2+), diagnosed within 3 years after sample collection.ResultsA total of 3225 women (mean [SD] age, 37.9 [11.3] years) participated in the study. For triage of HPV-positive women with partial genotyping, DS showed better risk stratification for CIN3+ than did Papanicolaou cytologic testing, with women with positive DS results having a higher risk than women with positive Papanicolaou test results for CIN3+ (218 of 1818 [12.0%; 95% CI, 10.5%-13.5%] vs 219 of 2128 [10.3%; 95% CI, 9.0%-11.6%];P = .005). Similarly, DS showed better risk stratification for CIN3+ compared with Papanicolaou cytologic testing in HPV-positive women, irrespective of genotyping. The greatest reassurance against CIN3+ was observed in HPV16/18-negative women with negative DS results, with a risk low enough to extend retesting intervals. Dual stain triage strategies required substantially fewer colposcopies per detection of CIN3+ compared with Papanicolaou cytologic testing, with a 32.1% (859 of 2677) reduction of colposcopies compared with the currently recommended triage strategy of HPV screening with Papanicolaou cytologic testing. Results for CIN2+ were very similar.Conclusions and RelevanceTriage of HPV-positive women with DS was superior to Papanicolaou cytologic testing in this study, demonstrating equal immediate detection of precancerous lesions and substantially reduced referral to colposcopy. These findings suggest that DS can safely replace Papanicolaou cytologic testing as a triage strategy for primary HPV screening, and that retesting intervals in HPV16/18-negative women with negative DS results can be safely extended to 3 years.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women

Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program

p16/Ki-67 dual-stained cytology used for triage in cervical cancer opportunistic screening.

Clinical Significance of Genotyping for Human Papillomavirus (HPV) 16 18/45 Combined with Cytology in Cervical Exfoliated Cells in HPV Oncogenic Mrna-Positive Women

Recommendations for Use of p16/Ki67 Dual Stain for Management of Individuals Testing Positive for Human Papillomavirus

Enhancing Cervical Cancer Screening: Review of p16/Ki-67 Dual Staining as a Promising Triage Strategy

Performance of P16/Ki67 Dual Staining in Triaging Hr-Hpv-positive Population During Cervical Cancer Screening in the Younger Women.

The Performance of Immunocytochemistry Staining As Triaging Tests for High-Risk HPV-Positive Women: A 24-Month Prospective Study

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.

Performance of Human Papillomavirus (HPV) 16 and 18/45 Genotyping Combined with Age Stratification in the Triaging of Women with Histologic Low-Grade Squamous Intraepithelial Lesions Preceded by HPV Oncogenic Mrna-Positive/normal or Mildly Abnormal Cytology: A Longitudinal Study

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology

Management of high-risk HPV-positive women for detection of cervical (pre)cancer

Evaluation of p16/Ki-67 Dual-Stained Cytology in Triaging HPV-Positive Women during Cervical Cancer Screening

p16/Ki67 dual stain triage versus cytology in primary human papillomavirus‐based cervical cancer screening with limited genotyping

Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women

Performance of HPV genotyping combined with p16/Ki-67 in detection of cervical precancer and cancer among HPV-positive Chinese women.

Risk Factors Triage on High-Risk Human Papillomavirus Testing Screening.

Application of p16/Ki-67 dual-staining cytology in cervical cancers

Evaluation of P16/ki-67 Dual Staining in the Detection of Cervical Precancer and Cancer in China.

Human Papillomavirus (HPV) E6/E7 Mrna Detection in Cervical Exfoliated Cells: a Potential Triage for HPV-positive Women

Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China